OS Therapies Incorporated
AMEX:OSTX · New York Stock Exchange American
+$0.10 today
Vol 1.14M · Avg 0.71M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$28.8B -323597.5% | -$8.9M -14.0% | -$7.8M -24.6% | -$6.3M +15.7% | -$7.4M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $363.1M +13060511.5% | $2.8K -34.1% | $4.2K +424.2% | $805 +0.0% | $805 | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $4.3B +1589895.2% | $268.3K | $0 | $0 | $0 | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $9.1M +7126.5% | -$129.6K -106.4% | $2.0M +112.9% | $947.3K +64.8% | $574.7K | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $0 | $0 | $0 | $0 | $0 | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $8.3M +885.5% | -$1.1M -178.2% | $1.3M +522.7% | $216.4K -74.7% | $856.5K | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $834.8K -9.6% | $923.7K +37.9% | $669.6K -8.4% | $730.9K +359.4% | -$281.8K | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $9.9B +676784.8% | $1.5M -47.2% | $2.8M +82.5% | $1.5M -38.0% | $2.4M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$14.2B -195423.2% | -$7.3M -142.2% | -$3.0M +20.7% | -$3.8M +13.9% | -$4.4M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$466.4K | $0 | $0 | $0 +100.0% | -$11.9K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$466.0M | $0 -100.0% | $1.1K -99.5% | $230.9K +8.7% | $212.4K | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$466.4M | $0 -100.0% | $1.1K -99.5% | $230.9K +15.2% | $200.5K | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 -100.0% | $1.5M -52.5% | $3.2M -17.4% | $3.8M +29.6% | $3.0M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $8.4M +60.5% | $5.2M | $0 | $0 | $0 | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 +100.0% | -$31.3M | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $9.4B +30082.0% | $31.3M +11096.7% | -$284.2K -65.2% | -$172.0K -272.0% | $100.0K | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $9.4B +73793.9% | $12.8M +344.7% | $2.9M -21.3% | $3.7M +19.7% | $3.1M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$5.3B -95898.6% | $5.5M +4246.9% | -$132.5K -246.1% | $90.7K +107.9% | -$1.2M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$14.2B -195423.2% | -$7.3M -142.2% | -$3.0M +20.7% | -$3.8M +14.1% | -$4.4M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Adagene Inc.
NASDAQ:ADAG
$138.36M
Equillium, Inc.
NASDAQ:EQ
$107.81M
Spruce Biosciences, Inc.
NASDAQ:SPRB
$70.24M
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
$69.75M
Outlook Therapeutics, Inc.
NASDAQ:OTLK
$64.11M
MiNK Therapeutics, Inc.
NASDAQ:INKT
$59.11M
Coeptis Therapeutics, Inc.
NASDAQ:COEP
$55.98M
CervoMed Inc.
CRVO
$37.87M
Werewolf Therapeutics, Inc.
HOWL
$17.18M
IO Biotech, Inc.
IOBT
$885,690.00
SEC Filings
Recent regulatory filings
No filings found.
Does OSTX generate free cash flow?
OS Therapies Incorporated (OSTX) generated -$14,238,576,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does OSTX produce?
Operating cash flow was -$14,238,576,000.00, before capital expenditures of $466,423.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.